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Introduction
Cancer remains one of the main underlying causes of morbidity and mortality (Curado et al., 2007) . Current treatments are far from optimal, having undesirable side-effects due to their non-selective nature (Grahame- Smith and Aronson, 2006) . Thus, new improved chemotherapeutic strategies are urgently required.
Iron is an essential co-factor for the catalytic activity of many enzymes including ribonucleotide reductase (RR), which catalyzes the rate-limiting step in DNA synthesis (Kolberg et al., 2004) . As neoplastic cells are generally more metabolically active than their normal counterparts, they require larger amounts of iron (Pahl and Horwitz, 2005) . In fact, cancer cells express high levels of transferrin receptor 1 (TfR1), which is responsible for iron uptake from the iron transport protein, transferrin (Tf) (Richardson and Baker, 1990; Trinder and Baker, 2003) . High expression of TfR1 has been demonstrated to correlate with tumor growth and metastasis in animal models (Cavanaugh et al., 1999) . In addition, cancer cells have been shown to express greater levels of RR in comparison to normal cells (Elford et al., 1970) . Considering this, cancer cells could be expected to be more sensitive to irondeprivation than normal cells (Le and Richardson, 2002) .
In the search for more effective anti-cancer agents, iron chelators have emerged as a novel class of chemotherapeutics worthy of investigation. The chelator, desferrioxamine (DFO; Figure 1A ), is classically used for the treatment of iron overload disease, but has also been assessed for anti-cancer activity ( Kalinowski and Richardson, 2005) . However, its poor membrane permeability due to its relative hydrophilicity, short half-life and relatively low anti-proliferative activity, has resulted in mixed outcomes in clinical trials (Kalinowski and Richardson, 2005) . This has led to studies examining iron chelators of greater lipophilicity. This article has not been copyedited and formatted. The final version may differ from this version. In comparison to hydrophilic DFO, the relatively hydrophobic iron chelator, pyridoxal isonicotinoyl hydrazone (PIH; Figure 1B ) is able to bind Fe III with high selectivity, inducing the mobilization of intracellular iron from a number of cell types (Huang and Ponka, 1983;  Richardson, 1997; Richardson and Ponka, 1994) . Interestingly, although PIH can effectively mobilize iron from cells, it appears to target iron pools that are not necessary for proliferation, demonstrating poor anti-proliferative activity in cell culture (IC 50 : 75 µM) (Richardson et al., 1995) .
A series of structure-activity relationship studies of the PIH analogues over the last 10 years has assessed both anti-proliferative efficacy and iron chelation activity (Becker et al., 2003; Richardson et al., 1995; Whitnall et al., 2006; Yuan et al., 2004) . This work has led to the development of the 2-benzoylpyridine thiosemicarbazone (BpT) chelators, which demonstrate potent and selective anti-cancer activity (Kalinowski et al., 2007) . These ligands have the ability to sequester cellular iron, as well as the capacity to form iron complexes that are redox-active (Kalinowski et al., 2007) . Hence, the BpT analogues are able to cause iron mobilization and generate cytotoxic reactive oxygen species (ROS), providing a novel approach for the inhibition of cancer cell growth (Kalinowski et al., 2007) .
Although the BpT series possess anti-proliferative activity in SK-N-MC neuroepithelioma cells (IC 50 : 0.002-0.005 µM; Kalinowski et al., 2007) , they show 1,250-3,000-fold less efficacy for inhibiting the proliferation of normal MRC-5 fibroblasts (IC 50 > 6.25 μ M) (Kalinowski et al., 2007) . Moreover, BpT chelators are effective in vivo, selectively inhibiting the growth of human tumor xenografts in nude mice (Yu, Y. and Richardson, D.R., unpublished results) . Within the BpT series, 2-benzoylpyridine 4-ethyl-3-thiosemicarbazone (Bp4eT; Figure 1C ), showed marked anti-proliferative activity with an IC 50 of 0.002 µM and This article has not been copyedited and formatted. The final version may differ from this version. (Kalinowski et al., 2007) .
While Bp4eT possessed potent and selective anti-cancer activity, the exact mechanisms behind these important properties remain unclear. Thus, the aim of the current study was to investigate the mechanisms of action of the potent anti-proliferative activity of Bp4eT in comparison to PIH, which exhibits poor anti-proliferative efficacy. In order to do this, 14 Clabeled chelators were employed. Since chemotherapeutic cytotoxicity depends on a variety of factors, including drug transport across membranes and retention within cells (Gottesman et al., 2002) , both the cellular uptake and release of 14 C-chelators were examined. In this investigation, the effects of temperature, metabolic inhibitors, pH and extracellular protein on the cellular retention of the chelators were measured. In addition, the cellular uptake of This article has not been copyedited and formatted. The final version may differ from this version. 
Cell Culture
The human SK-N-MC neuroepithelioma cell line (American Type Culture Collection (ATCC), Manassas, VA) was grown as previously described (Richardson et al., 1995) . Briefly, the cells were grown in minimal essential medium (MEM; Invitrogen, Victoria, Australia) with 10% (v/v) fetal calf serum (Sigma-Aldrich, St. Louis, USA) and supplemented with the following additions from Gibco (Victoria, Australia): 1% (v/v) sodium pyruvate, 1% (v/v) non-essential amino acids, 100 U/mL penicillin, 100 µg/mL streptomycin, 2 mM glutamine and 0.28 ng/mL fungizone. The cells were then incubated at 37 o C in a humidified atmosphere of 5% CO 2 /95% air in a water-jacketed incubator (Thermo Scientific, Forma Series II, Marietta, OH, USA). The SK-N-MC cell line was chosen for the majority of these investigations as its iron metabolism and the effect of a variety of chelators on this cell type is well characterized (Richardson and Ponka, 1994; Richardson et al., 1995 
General
14
C-Chelator Cellular Uptake Procedure
The 14 C-chelator uptake into cells was examined using the SK-N-MC cell line by implementing standard protocols (Huang and Ponka, 1983; Richardson, 1997 
The Effect of Metabolic Inhibitors on 14 C-Chelator Uptake
The effect of metabolic inhibitors on the uptake of 14 C-chelators was studied using five well remainder of the experiment was conducted using the general uptake procedure described above. During these studies, Dulbecco's modified Eagle's medium without glucose (DMEM -GLU; Invitrogen) was used to aid the ATP-depletion induced by the metabolic inhibitors (Richardson, 1997) . Results were expressed as a percentage of the control, namely DMEM + GLU.
General
14
C-Chelator Cellular Efflux Procedure
The release of the 14 C-chelators from pre-labeled SK-N-MC cells was performed using well established techniques (Huang and Ponka, 1983; Richardson, 1997; Richardson et al., 1995) . At the end of each incubation period, the cells were placed on ice and the overlying media was placed into counting tubes to estimate the level of extracellular 14 C-chelator. Then PBS (1 mL) was added to the cells which were subsequently scraped from the plates using a plastic spatula. This suspension was placed into counting tubes to represent the fraction of intracellular 14 C-chelator. Scintillation fluid (2.5 mL) was added to each sample as well as the backgrounds and standards and the tubes were counted using a Micro-Beta Counter. It should be noted that the inhibitor, 2,4-DNP, was not used in efflux studies due to problems associated with its intense color that led to quenching and thus problems associated with quantification of 14 C by β -counting. On the other hand, in uptake experiments, the inhibitors were washed off cells prior to β -counting, and thus, quenching did not affect the counting efficiency of 2,4-DNP-treated samples.
The Effect of Metabolic Inhibitors on
Cellular ATP Determination
Parallel ATP determinations were performed simultaneously in uptake and efflux experiments involving the use of metabolic inhibitors in order to confirm their inhibitory effects on energy metabolism. ATP levels were quantitatively analyzed using an ATP bioluminescence assay kit This article has not been copyedited and formatted. The final version may differ from this version. o C for 45 min at 14,000 rpm. The ATP assay mix (100 µL) was added to a 96-well plate, mixed and allowed to stand 3 min at room temperature to remove any endogenous ATP. The sample supernatant (100 µL) was then added to the ATP assay mix, shaken and the fluorescence was measured on a microplate reader (560 nm). A new standard curve was generated with each assay using the ATP standard supplied.
Statistical Analysis
Results are expressed as mean ± S.E.M. Statistical significance was determined using the Student's t-test, one-way ANOVA or two-way ANOVA with replication. Results were considered statistically significant when p < 0.05.
This article has not been copyedited and formatted. The final version may differ from this version. 
Results
Rate of 14 C-Chelator Uptake
The BpT series of ligands have shown high anti-proliferative activity and selectivity against cancer cells (Kalinowski et al., 2007) . To further understand their mechanism of action the current studies have assessed the ability of one of the most potent members of this series of compounds, namely Bp4eT, to permeate cancer cell membranes. For comparison to Bp4eT, we have assessed the uptake of the chelator, PIH, which shows some structural similarity (Figure 1 ), but demonstrates poor anti-proliferative activity (Richardson et al., 1995) . By determining the cellular uptake and subsequent release of these ligands, information relevant to their marked differences in anti-proliferative activity should be obtained.
In initial studies, the uptake of 14 C-Bp4eT and 14 C-PIH were measured after a 120 min (Fig. 2C) . Thus, 14 C-Bp4eT release from cells was temperature-dependent in contrast to its uptake (Fig. 2B ).
This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 2C) . Additionally, the percentage of cellular 14 C-PIH released was significantly (Fig. 2C) . Therefore, the release of intracellular 14 C-PIH was also found to be temperature-dependent, as identified for its uptake (Fig. 2B ).
Considering the greater intracellular concentrations of 14 C-Bp4eT within cells ( 
The Effect of Metabolic Inhibitors on 14 C-Chelator Uptake
Considering the results described above, experiments were then performed to determine whether chelator uptake was energy-dependent ( Fig. 3A and B) . The effect of five well characterized metabolic inhibitors, namely NaN 3 , oligomycin, NaCN, 2,4-DNP and NaF ( Henderson and Zevely, 1984; Qian and Morgan, 1991; Richardson, 1997; Svec, 1985) , on these studies, ATP assays were performed in parallel to 14 C-ligand uptake experiments to assess the effects of the inhibitors on energy metabolism ( Fig. 3C and D) . Studies compared the effects on 14 C-ligand uptake in DMEM ± GLU (Fig. 3) . Furthermore, in all of these experiments, the metabolic inhibitors were added to DMEM -GLU to ensure ATP-depletion of cells (Richardson, 1997) .
Although the metabolic inhibitors, NaN 3 , oligomycin, NaCN, 2,4-DNP and NaF significantly (p<0.01) reduced cellular ATP levels in comparison to control medium (namely DMEM + GLU; Fig. 3C ), they did not significantly (p>0.05) decrease 14 C-Bp4eT uptake (Fig. 3A) . In fact, 2,4-DNP caused a significant (p<0.01) increase in intracellular 14 C-Bp4eT in comparison to control medium (Fig. 3A) . The increased uptake of 14 C-Bp4eT in the presence of 2,4-DNP could be consistent with non-specific adsorption of the 14 C-labeled ligand to the cell due to membrane damage, as observed for other molecules (Baker et al., 1992) . In contrast to 2,4-DNP, the inhibitors NaN 3 , oligomycin, NaCN and NaF had no significant (p>0.05) effect on 14 C-Bp4eT uptake compared to the control (DMEM + GLU). Overall, all five metabolic inhibitors had no inhibitory effects on 14 C-Bp4eT uptake, suggesting that 14 C-Bp4eT uptake is an energy-independent process.
In addition, no significant (p>0.05) inhibitory effect of the metabolic poisons was evident on the uptake of 14 C-PIH by cells as compared to the controls (Fig. 3B ). This was despite the effect of these inhibitors to significantly (p<0.01) reduce ATP levels relative to the control (DMEM + GLU; Fig. 3D ). Both 2,4-DNP and NaF increased 14 C-PIH uptake relative to the control (Fig. 3B) . Again, this may be due to membrane damage induced by the inhibitor, leading to increased non-specific adsorption of 14 C-PIH. In summary, these results suggest that energy-independent mechanisms may also be responsible for the uptake of 
The Effect of Metabolic Inhibitors on 14 C-Chelator Efflux
Further studies then examined the effect of metabolic inhibitors on the cellular release of 14 C- Bp4eT and 14 C-PIH to determine whether this was an energy-dependent process ( Fig. 4A and   B ). Again, cellular ATP levels were assessed simultaneously in order to confirm the inhibitory effects of the metabolic inhibitors ( Fig. 4C and D) . Although inhibitor-treated cells possessed significantly (p<0.001) lower levels of ATP than control medium (DMEM ± GLU; Fig. 4C and D), no significant (p>0.05) effect was observed on the cellular release of 14 C-Bp4eT and 14 C-PIH ( Fig. 4A and B) . These results indicated that the cellular release of 14 C-Bp4eT and 14 C-PIH occurred through an energy-independent mechanism, involving the passive diffusion of both these ligands across the cell membrane.
The Effect of pH on 14 C-Chelator Uptake
A common hallmark of malignant neoplasms is the Warburg effect, in which the tumor possesses a slightly acidic (pH 6.92-7.24) microenvironment (Helmlinger et al., 1997; Warburg, 1956) . Since the thiosemicarbazone classes of chelators are polyprotic , their net charge is dependent upon the pH of the solution. This can markedly alter membrane permeability and thus it was important to understand the potential influence the Warburg effect has on the cellular uptake of 14 C-Bp4eT and 14 C-PIH. Considering this, the pH of the medium was altered using a variety of buffers (see Materials and Methods) so that the final pH values were equal to 5.5, 6.5, 7.4 and 8.0
( Fig. 5A-D) . These experiments demonstrated that the initial cellular uptake of 14 C-Bp4eT was significantly (p<0.05) lower at pH 5.5 and 6.5 than at pH 7.4 between 5-30 min at 37 o C (Fig. 5A) . However, for the remainder of the incubation up to 120 min at 37 o C, there was no significant (p>0.05) difference in uptake compared to pH 7.4 (Fig. 5A) . At pH 8.0, the uptake This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 6B ).
C-Chelator Uptake in Normal and Cancer Cells
Our previous studies have shown that Bp4eT markedly inhibits the growth of cancer cells relative to normal cells both in vitro (Kalinowski et al., 2007) and in vivo (Yu, Y. and Richardson, D.R. unpublished data) . Moreover, it is essential that clinically used chemotherapeutic agents preferentially target cancer cells as opposed to normal tissue to minimize side effects (Grahame- Smith and Aronson, 2006) . Thus, the following experiments were designed to examine the differences in the uptake of higher intracellular levels of 14 C-Bp4eT in contrast to the normal MRC-5 and HUVEC cell types (Fig. 7A) . Additionally, the SK-N-MC cell line also showed significantly (p<0.05) increased intracellular levels of 14 C-Bp4eT compared to MRC-5 cells, although no significant (p>0.05) differences were evident in comparison to HUVEC cells. Furthermore, there was no significant (p>0.05) increase in the cellular uptake of 14 C-Bp4eT in SK-Mel-28 melanoma cells relative to normal cell types (Fig. 7A) . Interestingly, the uptake of 14 C-Bp4eT differed in sub-confluent cells and this may be due to the adherence of the ligand to the plastic substratum of the culture plates under sub-confluent conditions (Fig. 7B ). Under these conditions, similar levels of 14 C-Bp4eT uptake were observed in SK-N-MC and SK-Mel-28 cells compared to normal cell lines (Fig. 7B ). In contrast, significantly (p<0.05) higher intracellular levels of 14 C-Bp4eT were present in MCF-7 cells relative to that in normal cells.
Collectively, these results demonstrate that generally there is no clear difference in the uptake of 14 C-Bp4eT between normal and neoplastic cells. However, uptake of this ligand by MCF-7 breast cancer cells was greater than that found for the normal and also other neoplastic cells.
No significant increase in 14 C-PIH uptake by cancer cell lines relative to normal cells was observed under confluent conditions (Fig. 7C) . However, the uptake of 14 C-PIH was markedly and significantly (p<0.001) greater by HUVECs than any other neoplastic or normal cell type (Fig. 7C ). In addition, under sub-confluent conditions, 14 C-PIH uptake into normal MRC-5 cells was significantly (p<0.05) lower than all other cancer and normal cells (Fig. 7D) , demonstrating that 14 C-PIH showed no selective uptake under sub-confluent conditions. This article has not been copyedited and formatted. The final version may differ from this version. 
Discussion
The toxicity of anti-cancer drugs as well as tumor resistance remain major problems in oncology (Grahame- Smith and Aronson, 2006) . Common causes for resistance and toxicity to chemotherapeutic agents include insufficient drug delivery to the tumor, inadequate drug uptake and/or rapid efflux (Gottesman et al., 2002) . Consequently, the current studies were undertaken to examine the membrane transport of the potential anti-tumor agent, Bp4eT.
Bp4eT Rapidly Enters Cells via a Metabolic Energy-Independent Mechanism Consistent with Diffusion
As part of this study, the uptake of 14 C-Bp4eT, which possesses marked anti-cancer activity (Kalinowski et al., 2007) , was compared to 14 C-PIH, a ligand with low anti-proliferative activity (Richardson et al., 1995) . The rate of 14 C-Bp4eT uptake by cells was markedly greater than that of 14 C-PIH ( Fig. 2A) , illustrating that 14 C-Bp4eT can more easily and rapidly permeate cells. This can be attributed to the lipophilic nature of Bp4eT (log P 4.02; Kalinowski et al., 2007) , in contrast to the relatively more hydrophilic ligand, PIH (log P -2.11) (Richardson et al., 1995) . Numerous studies have shown that hydrophilic chelators possess poor anti-proliferative activity, while compounds with relatively high lipophilicity have potent anti-proliferative effects (Hodges et al., 2004; Richardson et al., 1995) .
Consequently, the higher intracellular levels of 14 C-Bp4eT, owing to its greater membrane permeability, may be partly responsible for its potent anti-cancer activity (Kalinowski et al., 2007) . In contrast, the relatively hydrophilic 14 C-PIH led to lower membrane permeability, correlating with its poor anti-proliferative activity (Richardson et al., 1995) .
Since some transporters can influence cellular drug retention, such as the multi-drug resistance associated protein and P-glycoprotein (Gottesman et al., 2002) , it was important to This article has not been copyedited and formatted. The final version may differ from this version. Fig. 2A ) demonstrated that uptake occurred by zeroorder kinetics and remained unsaturated throughout the broad concentration range employed.
Second, 14 C-Bp4eT uptake by cells was not reduced despite depleting ATP stores using metabolic inhibitors (Fig. 3A, C) . The third piece of evidence demonstrating that 
Bp4eT and PIH are Released from Cells by a Temperature-Dependent Mechanism, but Hydrophobic Bp4eT is Sequestered in Cells Relative to PIH
Although it is important for adequate quantities of drug to permeate cells, it is also essential they evade efflux to allow sufficient quantities to be retained to cause cytotoxicity (Gottesman et al., 2002) . Therefore, to understand why Bp4eT was a more potent anti-cancer drug than PIH, 14 C-chelator efflux was investigated. In these studies, Bp4eT and PIH demonstrated a significant reduction in 14 C-chelator release at 4 o C than 37 o C (Fig. 2C) . These findings are consistent with a temperature-dependent release mechanism and may result from: (1) a change in membrane fluidity that occurs upon decreasing temperature affecting drug transport (Zimmer and Schirmer, 1974) ; or (2) a decrease in the efficacy of an energy-dependent transporter. To clarify this, additional efflux experiments performed with metabolic inhibitors (Fig. 4A and B) showed no difference in the release of intracellular MOL #66126 23 the control, despite a marked decrease in ATP. This indicated the mechanism of ligand release was energy-independent, but temperature-dependent. Hence, Bp4eT transport occurs via temperature-dependent passive diffusion, where membrane fluidity can affect membrane transport.
Importantly, the percentage of 14 C-PIH released from cells was significantly higher than that of 14 C-Bp4eT at 37°C (Fig. 2C) . These results together with the rapid uptake of 14 C-Bp4eT (Fig. 2B) , resulted in 32-fold higher levels of 14 C-Bp4eT relative to 14 C-PIH within cells (Fig.   2D ). The marked permeability and increased retention of 14 C-Bp4eT may be partly responsible for its potent anti-cancer effects, resulting in increased intracellular ROS and cell death ( Kalinowski and Richardson, 2005; Kalinowski et al., 2007) . This is facilitated by the difference in the iron-binding site of Bp4eT (N,N,S) relative to PIH (O,N,O) (Figure 1 ), which leads to the ability of Bp4eT to bind metals and redox cycle to generate ROS (Kalinowski et al., 2007) .
The Warburg Effect Does Not Influence Bp4eT Uptake or Release by Tumor Cells
Tumors often contain a slightly acidic microenvironment due to enhanced glycolysis, which has been referred to as the Warburg effect (Warburg, 1956) . Considering the chelators used are polyprotic compounds, their charge is influenced by pH, which affects membrane permeability . Thus, the extracellular pH was 24 5B). These results suggest a greater amount of 14 C-PIH was present in its neutral form at a pH of 5.5-6.5, allowing higher permeability than at pH 7.4. This concept is consistent with the species distribution of PIH as a function of pH, where its neutral species predominates at pH 6 (Doungdee, 1995; .
In contrast, alterations in pH had no significant effect on 14 C-Bp4eT uptake (Fig. 5A ). These data indicate 14 C-Bp4eT is present largely as a neutral ligand between pH 5.5-8.0, resulting in facile passage across the cell membrane. This suggestion is in accordance with the predicted protonation constants of Bp4eT based on the structure of very similar DpT ligands, particularly Dp4eT . This latter compound predominantly exists in its neutral form in the pH range of 4-11 . Accordingly, although the tumor milieu varies with respect to pH in accordance with the Warburg effect (Warburg, 1956) , it is unlikely it would influence Bp4eT uptake.
Extracellular Protein Increases Efflux of Bp4eT, but not PIH
Another factor in tumors which could affect the retention of these compounds is the quantity of protein in the interstitial fluid. Tumors possess more permeable blood vessels (Carmeliet and Jain, 2000) , which result in higher levels of proteins within the tumor interstitium (Greish, 2007; Maeda, 2001) . Hence, studies were performed in the presence of common proteins present in the interstitial fluid, namely Tf and albumin, to determine whether the protein microenvironment of tumors affects the cellular retention of the 14 C-labeled ligands.
These investigations demonstrated 14 C-Bp4eT release was increased in the presence of proteins compared to protein-free media and was independent of the protein type (Fig. 6A ).
Since lipophilic ligands have an affinity for proteins, these macromolecules may act as an extracellular "sink", increasing release of intracellular 14 C-Bp4eT (Buss et al., 2002; Buss et MOL #66126 25 al., 2003) . It is also notable that low levels of extracellular protein (5 mg/mL) resulted in similar efflux of 14 C-Bp4eT as high concentrations of protein (40 mg/mL). Thus, the higher protein levels within tumor interstitial fluid due to increased permeability of tumor vasculature (Carmeliet and Jain, 2000) , will probably not promote 14 C-Bp4eT release to any greater extent than in normal tissues. Conversely to Bp4eT, the presence of protein in medium had no marked effect on 14 C-PIH efflux at either protein concentration examined (Fig. 6B ).
These observations could be interpreted to suggest the added proteins preferentially bind the hydrophobic ligand, Bp4eT, to a greater extent than the more hydrophilic chelator, PIH.
All Cancer Cell Lines did not Preferentially Accumulate Higher Intracellular Levels of Bp4eT Relative to Normal Cells
Effective chemotherapy requires compounds to preferentially target cancer cells over normal cells to minimize systemic toxicity (Grahame- Smith and Aronson, 2006) . Previous studies demonstrated that Bp4eT has selective anti-proliferative activity in vitro (Kalinowski et al., 2007) and in vivo (Yu, Y. and Richardson, D.R. unpublished results) . Furthermore, closely related compounds of the DpT class showed selective anti-tumor activity in vivo (Whitnall et al., 2006) . Therefore, 14 C-chelator uptake was compared between cancer and normal cells.
Although increased 14 C-Bp4eT uptake was evident in MCF-7 cancer cells in comparison to normal cells, this difference was not apparent in all tumor cell types ( Fig. 7A and B) . Thus, other factors may be responsible for the selective anti-cancer activity of Bp4eT. These could include the greater sensitivity of cancer cells to iron-deprivation, as well as their effect on other iron-dependent targets, including: RR, the metastasis suppressor NDRG1, cyclin D1 etc ( Le and Richardson, 2004; Yu et al., 2007) .
In conclusion, 14 C- Bp4eT and 14 C-PIH uptake occurs through passive diffusion. Interestingly, This article has not been copyedited and formatted. The final version may differ from this version. 
